AMENDMENTS TO THE CLAIMS

Please cancel claims 1-52.

Please add new claims 53-83, a shown in the following list of claims:

- 1.-52. (Canceled).
- 53. (New) An ApoA-I agonist compound comprising:
 - (i) a 18 to 22-residue peptide analogue that forms an amphipathic α -helix in the presence of lipids and that comprises formula (I):

 $Z_{1}-X_{1}-X_{2}-X_{3}-X_{4}-X_{5}-X_{6}-X_{7}-X_{8}-X_{9}-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-Z_{2}$ or a pharmaceutically acceptable salt thereof, wherein

X₁ is Pro (P), Ala (A), Gly (G), Asn (N), Gln (Q) or D-pro (p);

X₂ is an aliphatic residue;

 X_3 is Leu (L);

X₄ is an acidic residue;

 X_5 is Leu (L) or Phe (F);

 X_6 is Leu (L) or Phe (F);

 X_7 is a basic residue;

X₈ is an acidic residue;

 X_9 is Leu (L) or Trp (W);

 X_{10} is Leu (L) or Trp (W);

 X_{11} is an acidic residue or Asn (N);

X₁₂ is an acidic residue;

 X_{13} is Leu (L), Trp (W) or Phe (F);

 X_{14} is a basic residue or Leu (L);

 X_{15} is Gln (Q) or Asn (N); X_{16} is a basic residue;

 X_{17} is Leu (L);

 X_{18} is a basic residue;

 Z_1 is H_2N_- , or $RC(O)NR_-$;

 Z_2 is -C(O)NRR, -C(O)OR or -C(O)OH or a salt thereof;

each R is independently -H, (C₁-C₆) alkyl, (C₁-C₆) alkenyl, (C₁-C₆) alkynyl,

(C₅-C₂₀) aryl, (C₆-C₂₆) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 4-residue peptide or peptide analogue;

each "-" between residues X1 through X18 independently designates an

amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic, wherein at least one "-" is a substituted amide linkage, an isostere of an amide or an amide mimetic;

- (ii) a 15 to 21-residue peptide analogue according to formula (I) in which at least one and up to eight of residues X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , X_7 , X_8 , X_9 , X_{10} , X_{11} , X_{12} , X_{13} , X_{14} , X_{15} , X_{16} , X_{17} and X_{18} are optionally deleted and wherein at least one "-" is a substituted amide linkage, an isostere of an amide or an amide mimetic; or
- (iii) an 18 to 22-residue altered peptide analogue according to formula (I) in which at least one of residues X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇ and X₁₈ is conservatively substituted and wherein at least one "-" is a substituted amide linkage, an isostere of an amide or an amide mimetic; or an N-terminally blocked form, a C-terminally blocked form or an N- and C-terminally blocked form of formula (I).
- 54. (New) The ApoA-I agonist compound of Claim 53 which exhibits at least about 38% LCAT-activation activity as compared with human ApoA-I.
- 55. (New) The ApoA-I agonist compound of Claim 54 wherein at least one "-" is a substituted amide linkage.
- 56. (New) The ApoA-I agonist compound of Claim 55 wherein the substituted amide linkage has the formula -C(O)NR-, where R is (C₁-C₆) alkyl, substituted (C₁-C₆) alkyl, (C₁-C₆) alkenyl, substituted (C₁-C₆) alkenyl, (C₁-C₆) alkynyl, substituted (C₁-C₆) alkynyl, (C₅-C₂₀) aryl, substituted (C₅-C₂₀) aryl, (C₆-C₂₆) alkaryl, substituted (C₆-C₂₆) alkaryl, 5-20 membered heteroaryl, substituted 5-20 membered heteroaryl, 6-26 membered alkheteroaryl, or substituted 6-26 membered alkheteroaryl.
- 57. (New) The ApoA-I agonist compound of Claim 54 wherein the least one "-" is an isostere of an amide.
- 58. (New) The ApoA-I agonist compound of Claim 57 wherein the isostere of an amide is -CH₂NH-, -CH₂S-, CH₂CH₂-, -CH=CH- (cis and trans), -C(O)CH₂-, -CH(OH)CH₂-, or -CH₂SO-.

- 59. (New) The ApoA-I agonist compound of Claim 54 wherein the peptide analogue forms an amphipathic α -helix in the presence of lipids.
- 60. (New) The ApoA-I agonist compound of Claim 54 wherein the peptide analogue exhibits 40% to 98% helicity in the presence of lipids.
- 61. (New) The ApoA-I agonist compound of Claim 54 wherein the peptide analogue comprises 40% to 70% hydrophobic residues.
- 62. (New) The ApoA-I agonist compound of Claim 61 wherein the peptide analogue comprises 50% to 60% hydrophobic residues.
- 63. (New) The ApoA-I agonist compound of Claim 54 wherein the mean hydrophobic moment, $\langle \mu_H \rangle$, of the peptide analogue is 0.55 to 0.65.
- 64. (New) The ApoA-I agonist compound of Claim 63 wherein the mean hydrophobic moment, $\langle \mu_H \rangle$, of the peptide analogue is 0.58 to 0.62.
- 65: (New) The ApoA-I agonist compound of Claim 54 wherein the mean hydrophobicity, $<H_o>$, of the peptide analogue is -0.150 to -0.070.
- 66. (New) The ApoA-I agonist compound of Claim 65 wherein the mean hydrophobicity, $\langle H_o \rangle$, of the peptide analogue is -0.130 to -0.050.
- 67. (New) The ApoA-I agonist compound of Claim 54 wherein the mean hydrophobicity of the hydrophobic face, $\langle H_o^{pho} \rangle$, of the peptide analogue is 0.90 to 1.20.
- 68. (New) The ApoA-I agonist compound of Claim 67 wherein the mean hydrophobicity of the hydrophobic face, $\langle H_o^{pho} \rangle$, of the peptide analogue is 0.95 to 1.10.
- 69. (New) The ApoA-I agonist compound of Claim 54 wherein the pho angle of the peptide analogue is 120° to 160°.
- 70. (New) The ApoA-I agonist compound of Claim 69 wherein the pho angle of the peptide analogue is 130° to 150°.

Preliminary Amendment Page 10 of 13 CAJD: 501365.1

- 71. (New) The ApoA-I agonist compound of Claim 54 wherein the peptide analogue has 3 to 5 positively charged amino acids.
- 72. (New) The ApoA-I agonist compound of Claim 54 wherein the peptide analogue has 3 to 5 negatively charged amino acids.
- 73. (New) The ApoA-I agonist compound of Claim 54 wherein the peptide analogue has a net charge of -1, 0, or +1.
- 74. (New) An ApoA-I agonist-lipid complex comprising an ApoA-I agonist compound and a lipid, wherein the ApoA-I agonist compound is a peptide analogue according to any one of claims 53-73.
- 75. (New) A pharmaceutical composition comprising an ApoA-I agonist compound according to any one of claims 53-73 or an ApoA-I agonist-lipid complex according to claim 74, and a pharmaceutically acceptable carrier, excipient or diluent.
- 76. (New) A method of treating a subject suffering from a disorder associated with dyslipidemia, said method comprising the step of administering to the subject an effective amount of the ApoA-I agonist compound of claim 53.
- 77. (New) The method of Claim 76 in which the disorder associated with dyslipidemia is hypercholesterolemia.
- 78. (New) The method of Claim 76 in which the disorder associated with dyslipidemia is cardiovascular disease.
- 79. (New) The method of Claim 76 in which the disorder associated with dyslipidemia is atherosclerosis.
- 80. (New) The method of Claim 76 in which the disorder associated with dyslipidemia is restenosis.

- 81. (New) The method of Claim 76 in which the disorder associated with dyslipidemia is HDL or ApoA-I deficiency.
- 82. (New) The method of Claim 76 in which the disorder associated with dyslipidemia is hypertriglyceridemia.
- 83. (New) The method of Claim 76 in which the disorder associated with dyslipidemia is metabolic syndrome.